Pricing Log in Create free account
Saturday 17 October 2026 Export SNN’s income statement to Excel — free account

Smith & Nephew SNATS, Inc.

SNN Healthcare Medical Devices

Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024. Revenue growth for five consecutive years, operating cash flow growth for three.

29.06 0.03 −0.10%
Market cap
$12.2B
P/E
35.4×
Fwd P/E
18.6×
Dividend yield
2.73%
F-score
7/9
Altman Z
3.49
Beneish M
−2.70
Dividend safety
61/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 6.93%

Capital & Financial Ratios $m

Market Cap 12,170.00
Revenue 10,498.22
Net Income 2,019.00
Free Cash Flow 2,025.00
Net Debt 2,458.00
Current Ratio 2.14 (at or above 1.5: strong)
Debt/Equity 0.62
P/E ratio 35.42 (above 35: high)
Fwd P/E 18.60
P/S ratio 1.24
P/B ratio 2.52
Past 5Y EPS Growth 7.02%
This Y EPS Growth 7.52%
Next Y EPS Growth 8.91%
Next Y revenue growth 38.03% (at or above 10%: strong)
Next 5Y EPS Growth 9.41%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.5×, against a ten-year median of 1.9×; over the ten years it ranged from 1.2× in 2023 to 4.1× in 2017.
P/E against its own 10 years 80.61%
10-year low 10-year high
P/S against its own 10 years 21.93%
10-year low 10-year high
P/B against its own 10 years 25.54%
10-year low 10-year high
EV/Sales against its own 10 years 21.82%
10-year low 10-year high
EV/FCF against its own 10 years 1.36%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate 0.79
Annual Dividend Yield 2.73%
total individual payouts
2028 Powerpack
2027 Powerpack
2026 0.53
0.48
0.31
2025 0.56
0.46
0.30
2024 0.75
0.46
0.29
2023 0.75
0.46
0.29
2022 0.75
0.46
0.29
2021 0.75
0.46
0.29
2020 0.75
0.46
0.29
2019 0.73
0.44
0.29
2018 0.73
0.45
0.28
2017 0.62
0.37
0.25
2016 0.63
0.38
0.25
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 302 619 557 754
Receivables 1,333 1,415 1,429 1,520
Inventory 2,395 2,387 2,117 2,113
Other — — — —
4,030 4,421 4,103 4,387
2023 2024 2025 Q'26
Payables 1,055 1,128 1,177 1,249
ST’ Debt — — — —
Other 451 340 268 229
2,271 1,531 1,595 2,051

Compound Annual Growth %

10y 5y 3y
Sales 2.89% 6.21% 5.73%
Cash Flow 2.24% 6.57% 40.03%
Earnings 4.31% 6.89% 40.99%
Book Value 2.92% 0.04% 0.19%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 6,164
’24 — — — — 5,810
’23 — — — — 5,549
’22 — — — — 5,215
’21 — — — — 5,212
’20 — — — — 4,560
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 1,285
’24 — — — — 987
’23 — — — — 608
’22 — — — — 468
’21 — — — — 877
’20 — — — — 935
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — 260 — — —
’25 — 269 — 890 890
’24 — 66 — 606 606
’23 — (54) — 181 181
’22 — 34 — 110 110
’21 — 188 — 469 469
’20 — (115) — 492 492
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 1.43
’24 — — — — 0.94
’23 — — — — 0.60
’22 — — — — 0.51
’21 — — — — 1.20
’20 — — — — 1.02
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 26.97 29.76 32.22 35.39 26.07 31.55 21.78 21.53 23.65 23.69

Analyst estimates 2026–2028

Powerpack
High 35.38 40.43 39.85 48.93 52.26 46.10 36.68 33.09 31.72 38.79
People
People Employees 15,644 15,933 16,377 17,637 18,000 18,000 19,012 18,452 17,349 16,988
Revenue/emp, $m 0.30 0.30 0.30 0.29 0.25 0.29 0.27 0.30 0.33 0.36
Income, $m
Income, $m Revenue 4,669 4,765 4,904 5,138 4,560 5,212 5,215 5,549 5,810 6,164
Gross margin, % 72.76 73.81 73.53 73.96 69.39 70.40 70.47 68.82 69.64 68.01
EBT 1,062 879 781 743 246 586 235 290 498 779
EBT margin, % 22.75 18.45 15.93 14.46 5.39 11.24 4.51 5.23 8.57 12.64
Net income 1,062 879 781 743 246 586 235 290 498 779
Depreciation 463 447 435 502 562 567 617 683 645 573
Per share, $
Per share, $ Revenue 10.49 10.90 11.23 11.76 10.42 11.89 11.96 12.74 13.31 14.22
Earnings 1.76 1.76 1.52 1.37 1.03 1.20 0.51 0.60 0.94 1.44
Cash flow 1.91 2.49 2.13 2.67 2.14 2.00 1.07 1.40 2.26 2.96
Capex (0.88) (0.86) (0.79) (0.93) (1.01) (0.93) (0.82) (0.98) (0.87) (0.91)
Free cash flow 1.03 1.63 1.34 1.74 1.12 1.07 0.25 0.42 1.39 2.05
Book value 8.89 10.63 11.17 11.76 12.07 12.70 12.06 11.98 12.06 12.20
Shares, m 445 437 437 437 438 439 436 436 437 434
Valuation, ×
Valuation, × P/E 26.63 30.99 30.51 32.50 34.97 30.83 31.96 32.73 29.96 39.99
P/S 2.92 3.40 2.81 2.43 1.92 1.58 1.19 1.15 1.05 1.40
P/B 3.41 3.38 3.45 4.20 3.59 2.79 2.33 2.31 2.10 2.79
EV/Sales 3.24 3.67 2.97 2.62 2.09 1.74 1.42 1.34 1.30 1.65
EV/FCF 9.10 8.40 11.15 13.23 14.32 16.55 18.26 51.97 17.13 9.48
Cash, $m
Cash, $m Operating cash flow 849 1,090 931 1,168 935 877 468 608 987 1,285
Capex (392) (376) (347) (408) (443) (408) (358) (427) (381) (395)
Free cash flow 457 714 584 760 492 469 110 181 606 890
Balance, $m
Balance, $m Working capital 1,181 1,385 1,612 1,655 2,976 2,293 2,141 1,759 2,890 2,508
Total debt 1,564 1,423 1,301 1,975 3,353 2,848 2,712 2,319 3,258 3,177
Net debt 1,464 1,254 936 1,698 1,591 1,558 2,362 2,017 2,639 2,620
Shareholders’ equity 3,958 4,644 4,874 5,141 5,279 5,568 5,259 5,217 5,265 5,289
Returns, %
Returns, % ROA 10.81 10.09 8.33 6.91 4.41 4.78 2.14 2.64 4.05 6.01
ROIC 9.23 9.90 9.28 7.45 2.68 5.20 3.69 3.67 5.20 6.27
ROE 19.79 17.83 13.93 11.98 8.60 9.66 4.12 5.02 7.86 11.84
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2014

Charts ten years each

Smith & Nephew SNATS, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ZBH Zimmer Biomet Holdings, Inc. $18.0B 23.0× 17.7× +4.80% (above 0%: growing) +33.77% (above 0%: growing) +13.05% (above 0%: growing) 70.81% 14.98% Compare
PEN Penumbra, Inc. $12.7B 78.4× 63.5× +14.90% (above 0%: growing) −24.79% (below 0%: shrinking) +10.81% (above 0%: growing) 67.93% 10.52% Compare
SNN Smith & Nephew SNATS, Inc. $12.2B 35.4× 18.6× +7.99% (above 0%: growing) −14.23% (below 0%: shrinking) +293.94% (above 0%: growing) 69.42% 0.00%
GMED Globus Medical, Inc. $10.6B 19.3× 20.3× +5.94% (above 0%: growing) −25.33% (below 0%: shrinking) +571.30% (above 0%: growing) 69.42% 23.10% Compare
BIO.B Bio-Rad Laboratories, Inc. $10.3B 43.7× — −0.09% (below 0%: shrinking) +19.02% (above 0%: growing) −6.06% (below 0%: shrinking) 53.12% 11.15% Compare
GKOS Glaukos Corporation $9.8B — (loss-making) — (loss-making) +49.54% (above 0%: growing) n/m +211.83% (above 0%: growing) 81.67% (9.30%) Compare
BIO Bio-Rad Laboratories, Inc. $9.8B 42.5× 35.4× −0.09% (below 0%: shrinking) +19.02% (above 0%: growing) −6.06% (below 0%: shrinking) 53.12% 11.15% Compare
PODD Insulet Corporation $9.6B 26.4× 24.7× +23.51% (above 0%: growing) +328.13% (above 0%: growing) −70.51% (below 0%: shrinking) 70.18% 16.18% Compare
BRKR Bruker Corporation $8.6B — (loss-making) 55.7× +5.15% (above 0%: growing) n/m +28.63% (above 0%: growing) 49.61% (7.79%) Compare
Median of peers $10.0B 34.4× 30.0× +5.55% +19.02% +11.93% 68.68% 11.15%

All 149 Medical Devices stocks →

Smith & Nephew SNATS, Inc. (SNN) key facts

  • Strength: Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
  • Strength: Net income was $779.0 million, or $1.44 per share (basic), a net margin of 10.1%.
  • Smith & Nephew SNATS, Inc. (SNN) is a Medical Devices company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, SNN traded at $29.06, a market capitalization of $12.2 billion.
  • At that price the stock trades at 35.4× trailing-twelve-month earnings and 1.2× sales; its P/E is higher than 81% of its own readings over the past ten years.
  • Smith & Nephew SNATS, Inc. pays an annual dividend of $0.79 per share, a yield of 2.73%.
  • Return on equity was 11.8% and debt-to-equity 0.62.
  • Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 3.49 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Smith & Nephew SNATS, Inc. (SNN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SNN · Data as of Dec 31, 2014 · For information only; not investment advice. · © 2026 stockrow.com